MDT-AP-3327
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 11
- sex
- F
- new_clusters
- C4
- umap1_2d
- 4.654342963
- umap2_2d
- 4.489500615
- umap1_3d
- 2.515392516
- umap2_3d
- -1.779513707
- umap3_3d
- -3.028109381
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.400
- PROTEIN_SECRETION+0.390
- MITOTIC_SPINDLE+0.380
- HEDGEHOG_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.180
- MTORC1_SIGNALING+0.150
- SPERMATOGENESIS+0.150
Top 10 suppressed
- ANGIOGENESIS-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- ALLOGRAFT_REJECTION-0.370
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.360
- APICAL_SURFACE-0.340
- INTERFERON_ALPHA_RESPONSE-0.330
- CHOLESTEROL_HOMEOSTASIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclc232230_S83.txt | — | cohortSC | 0.854 |
| 2 | msclc591T1_S51.txt | — | cohortSC | 0.847 |
| 3 | TCGA-AR-A0U2-01A-11R-A109-07 | — | B | 0.844 |
| 4 | MDT-AP-3021 | Med | Medulloblastoma | 0.844 |
| 5 | ERR2598213 | fetal | fetal | 0.843 |
| 6 | TCGA-E9-A1N9-01A-11R-A14D-07 | — | C | 0.840 |
| 7 | fd3ce752-3456-4aaf-bede-9cf5f0771b9d | — | — | 0.839 |
| 8 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.838 |
| 9 | BS_8QB4S4VA | Embryonal tumors | — | 0.823 |
| 10 | TCGA-G2-A2EL-01A-12R-A18C-07 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.060 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.030 | Idelalisib | — uncovered |